85 related articles for article (PubMed ID: 11873382)
1. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer.
Delea TE; Vera-Llonch M; Edelsberg JS; McGarry L; Anton S; Ulcickas-Yood M; Oster G
Value Health; 2002; 5(1):35-43. PubMed ID: 11873382
[TBL] [Abstract][Full Text] [Related]
2. Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost.
Oster G
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):41. PubMed ID: 10442358
[TBL] [Abstract][Full Text] [Related]
3. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
5. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
Crozier JE; McKee RF; McArdle CS; Angerson WJ; Anderson JH; Horgan PG; McMillan DC
Br J Cancer; 2006 Jun; 94(12):1833-6. PubMed ID: 16721360
[TBL] [Abstract][Full Text] [Related]
6. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
De Portu S; Mantovani LG; Ravaioli A; Tamburini E; Bollina R; Cozzi C; Grimaldi AM; Testa TE; Bianchessi C; Carteni G
J Chemother; 2010 Apr; 22(2):125-8. PubMed ID: 20435573
[TBL] [Abstract][Full Text] [Related]
9. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Chu E; Shi N; Wei W; Bendell JC; Cartwright T
Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Hoff PM; Pazdur R; Lassere Y; Carter S; Samid D; Polito D; Abbruzzese JL
J Clin Oncol; 2004 Jun; 22(11):2078-83. PubMed ID: 15169794
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
Witte RS; Cnaan A; Mansour EG; Barylak E; Harris JE; Schutt AJ
Cancer; 2001 Mar; 91(5):1020-8. PubMed ID: 11251955
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
[TBL] [Abstract][Full Text] [Related]
14. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
16. The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
Blijham GH
J Infus Chemother; 1996; 6(3):114-7. PubMed ID: 9229320
[TBL] [Abstract][Full Text] [Related]
17. Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
Matsuoka H; Nagaya M; Tsukikawa S; Yanagi Y; Isogai A; Kubota S
Surgery; 2006 Sep; 140(3):387-95. PubMed ID: 16934600
[TBL] [Abstract][Full Text] [Related]
18. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Loeffler TM; Hausamen TU
J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
[TBL] [Abstract][Full Text] [Related]
19. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
Lim L; Gibbs P; Yip D; Shapiro JD; Dowling R; Smith D; Little A; Bailey W; Liechtenstein M
BMC Cancer; 2005 Oct; 5():132. PubMed ID: 16225697
[TBL] [Abstract][Full Text] [Related]
20. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]